Equazen Pro, sold as a medical food to address fatty acid deficiencies common in people with ADHD and some related neurodiverse conditions that cannot be resolved by normal diet modification alone, is now available throughout the U.S. in major drug and mass-market retailers, online and in-store, according to SFI Health, a contract development and manufacturing Organization (CDMO).

In clinical trials among kids and teens with ADHD, the Equazen Pro formula showed on average significant improvements in focus, attention, academic performance, and balanced mood. Medical foods are intended to be used under medical supervision.

Backed by 15 years of research and 19 published clinical studies, including six clinical trials among kids and teens with ADHD, Equazen Pro is shown to be safe and effective to use as nutritional support along with common prescription ADHD medications, and improves focus and academic performance within 12 weeks.

Equazen Pro is said to work by providing an optimal balance of both omega-3 and omega-6 fatty acids. It is well established in Europe. With entry into the U.S., SFI Health is offering easy-to-swallow softgels, as well as jelly chews that are appropriate for children aged three and up.

Attention-deficit/hyperactivity disorder affects an estimated 6.1 million children in the U.S. and the diagnosis rate has gone up 42% between 2003 and 2011.

“Our purpose in bringing Equazen Pro to the U.S. is to provide a clinically proven, non-prescription, nutrition solution to help reduce ADHD symptoms. Studies show that Equazen Pro is safe and effective to use as nutritional support along with common prescription ADHD medications. What excites us most is advancing options available to parents, patients, and healthcare professionals,” said Divya Ramakrishnan, general manager for Americas at SFI Health.